Thank you very much, Mr. Chair.
At NACI, the National Advisory Committee on Immunization, we monitor the authorized vaccines or the vaccines that we expect to be authorized and make recommendations with regard to those vaccines. We're currently looking at the current vaccines and how we can best make use of them.
As new technologies become available—if we get future technologies that may, for instance, look at mucosal vaccination or vaccines that enhance other parts of our immune response such as T cell immunity—as those vaccines become authorized in Canada, NACI will look at those vaccines as well and make recommendations with regard to them.
We know that the whole scientific community is watching to see what the next types of vaccines will be. They're watching what the manufacturers will put out with regard to potentially multivalent vaccines—vaccines that cover the wild-type strain and the omicron strain—and whether those may be more beneficial for future boosting. As those become authorized or the manufacturers put those forward for authorization, we will then, within the national advisory committee, look at those as well and make recommendations in the context of the epidemiology and the other vaccines available for Canadians.